Genome-engineered porcine organs can replace failed human organs
PrimaryeGenesis' central causal theory is that organ failure can be treated by transplanting porcine organs that have been genetically engineered to be more compatible with human recipients. If multiplex genome edits can reduce xenogeneic immune injury, infectious risk, and physiologic incompatibility, then engineered porcine kidneys, hearts, and livers should function as life-sustaining organ replacements or bridges for patients with end-stage organ disease.
Testable predictions include sustained xenograft perfusion and organ-specific function in recipients, reduced acute rejection relative to unmodified pig organs, manageable immunosuppression requirements, and clinically meaningful survival or bridge-to-allotransplantation outcomes in kidney, heart, and liver failure settings.
company website · Sat Jun 20 2026 03:27:53 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The premise is biologically credible: genome editing can remove or soften known pig-to-human barriers, including xenogeneic immune triggers and porcine endogenous retrovirus risk. The strongest part is the mechanism. The weaker part is breadth. Kidney, heart, and liver xenografts do not fail through one shared bottleneck, so success in one organ does not prove the whole theory.
Supporting evidence: Extensive germline genome engineering in pigs has been reported, supporting the feasibility of multiplex-edited donor animals.; CRISPR inactivation of porcine endogenous retroviruses supports a direct route to reducing one infectious-risk concern.; A humanized porcine donor design was tested in 2023, supporting the claim that donor pigs can be engineered around known xenotransplant barriers.
Counter evidence: The theory assumes that edits reducing immune injury, infectious risk, and physiologic mismatch in early or preclinical settings will generalize across kidney, heart, and liver failure.; Clinical human evidence is still thin, especially outside kidney transplantation.
Explanatory power7.0
The theory explains several observed signals: functional kidney support, months-long pig-to-baboon cardiac survival, and bridge outcomes in liver-support settings all fit the claim that engineered porcine organs can perform organ work in recipients. But the evidence can also be explained by intensive recipient selection, aggressive immunosuppression, perioperative management, and organ-specific support protocols. The edits matter, but the data do not yet isolate how much of the outcome belongs to the genome design itself.
Supporting evidence: Life-sustaining kidney xenotransplantation showed clinical and molecular evidence consistent with physiological pathway activity.; A porcine kidney xenotransplant was reported in end-stage kidney disease, directly testing replacement in the target clinical setting.; In a pig-to-baboon pediatric cardiac model, gene-edited pig hearts supported some recipients for months, with the longest survivor living more than 24 months.
Counter evidence: The pig-to-baboon cardiac evidence remains preclinical and may not predict human cardiac xenotransplant performance.; Liver evidence cited here includes extracorporeal liver perfusion and bridge-to-transplantation outcomes, which is weaker evidence for full implanted liver replacement.; Manageable infection and rejection outcomes may depend heavily on screening, monitoring, immunosuppression, and clinical rescue capacity.
Falsifiability9.0
This theory is highly testable. It predicts perfusion, organ-specific function, rejection rates, immunosuppression burden, infection outcomes, survival, and bridge-to-allotransplantation. Those are measurable endpoints, and bad results would hurt the theory plainly: rapid thrombosis, hyperacute rejection, uncontrolled infection, absent organ function, or no survival benefit would count against it.
Supporting evidence: The theory predicts sustained xenograft perfusion and measurable organ-specific function.; It predicts less acute rejection than unmodified pig organs.; It predicts clinically manageable immunosuppression requirements.; It predicts survival or bridge-to-allotransplantation outcomes in kidney, heart, and liver failure.
Counter evidence: Some endpoints need sharper thresholds, such as minimum graft survival time, acceptable rejection rate, and infection-monitoring windows.; The multi-organ claim could survive partial failure unless kidney, heart, and liver programs are judged separately.
Reasoning tree
premiseOrgan failure can be treated by transplanting porcine organs that have been genetically engineered to be more compatible with human recipients.
medium confidence - 3 linked evidence items
premiserequires
Multiplex genome engineering can produce pigs with donor organs modified to reduce key xenotransplantation barriers.
high confidence - 3 linked evidence items
premiseimplies
Genome editing can inactivate porcine endogenous retroviruses, reducing a potential infectious risk of pig-to-human xenotransplantation.
high confidence - 3 linked evidence items
assumptionassumes
Infectious risk can remain manageable under immunosuppression through donor screening, pathogen mitigation, recipient monitoring, and infection prevention protocols.
medium confidence - 2 linked evidence items
assumptionassumes
Genetic edits that reduce xenogeneic immune injury, infectious risk, and physiologic incompatibility in preclinical or early clinical settings will generalize across human kidney, heart, and liver failure populations.
medium confidence - 4 linked evidence items
derivationimplies
If engineered pig organs avoid rapid immune destruction, uncontrolled infection, and major physiologic mismatch, they should be able to perfuse and perform organ-specific functions in recipients.
medium confidence - 3 linked evidence items
predictionpredicts
Recipients of engineered porcine xenografts should show sustained xenograft perfusion and measurable organ-specific function.
high confidence - 3 linked evidence items
observationobserved_in
Life-sustaining kidney xenotransplantation showed clinical and molecular evidence of physiological pathway activity consistent with functional xenograft support.
medium confidence - 1 linked evidence item
predictionpredicts
Engineered porcine organs should cause less acute rejection than unmodified pig organs.
medium confidence - 2 linked evidence items
predictionpredicts
Immunosuppression requirements for engineered porcine organ transplantation should be clinically manageable.
medium confidence - 3 linked evidence items
observationobserved_in
A clinical genetically modified porcine kidney transplant was performed in a human recipient with reported infectious disease surveillance, donor screening, recipient monitoring, infection prevention, and complication management strategies.
high confidence - 2 linked evidence items
predictionpredicts
Engineered porcine kidneys, hearts, and livers should produce clinically meaningful survival or bridge-to-allotransplantation outcomes in end-stage organ failure settings.
medium confidence - 3 linked evidence items
observationobserved_in
Xenotransplantation of a porcine kidney has been reported for end-stage kidney disease, directly testing kidney replacement in the target clinical setting.
high confidence - 1 linked evidence item
observationobserved_in
In a pig-to-baboon pediatric cardiac xenotransplantation model, gene-edited pig hearts sustained some recipients for months, with the longest survivor living more than 24 months after xenotransplantation.
high confidence - 2 linked evidence items
assumptionassumes
Preclinical nonhuman-primate xenotransplantation outcomes are sufficiently predictive of human clinical performance to justify translation.
medium confidence - 2 linked evidence items
observationobserved_in
In the pig-to-baboon cardiac model, prolonged xenograft exposure did not show evidence of significant xeno- or allo-sensitization before transition to allotransplantation in selected recipients.
medium confidence - 1 linked evidence item
observationobserved_in
Whole-organ extracorporeal liver perfusion reports in acute liver failure and acute-on-chronic liver failure bridged more than half of severe patients to transplantation and survival without reported porcine retrovirus transmission.
medium confidence - 2 linked evidence items
derivationimplies
Because kidney, heart, and liver failure are limited by shortage or inadequacy of replacement options, a scalable genetically engineered porcine organ supply would address an unmet clinical need.
medium confidence - 3 linked evidence items
project_implicationimplies
The project should prioritize demonstrating durable organ function, rejection control, infection surveillance, and survival or bridge outcomes in organ-specific kidney, heart, and liver xenotransplantation programs.
high confidence - 4 linked evidence items
Public endorsements
silent
The provided evidence does not show Bob More making any public statement about this theory. The listed records feature other people, including Mike Curtis, Leigh Peterson, Joe Tector, Elisa Gordon, and George Church, but not Bob More.
silent
The evidence only shows that Brad Smith joined eGenesis' board in June 2021. There is no public quote, publication, or attributed statement from him about the theory that genome-engineered porcine organs can replace failed human organs, so we cannot credit him with endorsing, mentioning, or contradicting it.
silent
The record shows Douglas Williams joined eGenesis' board in August 2025, and the company describes itself there as developing engineered organs. That establishes his formal relationship to the company, but this evidence does not show any public statement from Williams himself endorsing, discussing, or disputing the theory.
silent
The provided evidence shows Eliezer Katz was appointed eGenesis Chief Medical Officer in April 2022, but it does not include any public quote, statement, authored publication, or attributed remark from him about the theory that genome-engineered porcine organs can replace failed human organs. On this dossier, he is publicly present as an executive and otherwise silent on the theory itself.
mentions
George Church is publicly linked to eGenesis in two public video records that describe him as a cofounder, including one that explicitly calls eGenesis a xenotransplantation company. That is enough to show public association with the organ-replacement program, but the evidence here does not include a direct statement from Church backing the specific causal theory about engineered porcine organs functioning as human organ replacements.
Genome-engineered porcine organs can extend healthspan by replacing failing human organs
PrimaryeGenesis' central causal theory is that organ failure can be treated by transplanting porcine organs engineered to be more compatible with humans. If donor-organ scarcity is a limiting factor in survival and quality of life for patients with kidney, liver, or heart failure, then a scalable supply of human-compatible engineered organs should reduce time without adequate organ function, restore organ-specific physiology, and improve survival or functional health in patients with otherwise life-limiting disease.
Testable predictions include successful graft function after transplantation, reduced need for dialysis or organ-support devices, acceptable survival and complication rates, and clinical feasibility across kidney, liver, and heart programs.
company website · Mon Jun 08 2026 20:28:07 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The core premise is credible: end-stage kidney, liver, and heart failure can be treated by replacing the failed organ, and human donor scarcity is a real bottleneck. The harder claim is compatibility. The evidence supports the idea that pigs can be heavily edited for xenotransplantation, including immune and infectious-risk traits, but durable human performance across kidney, liver, and heart remains only partly shown.
Supporting evidence: Organ replacement is already a validated treatment principle for kidney, liver, and heart failure.; The evidence set cites donor-organ scarcity as a high-confidence constraint on survival and quality of life.; Pig genomes can be extensively engineered, including work on humanized porcine donors and porcine endogenous retrovirus inactivation.; Life-sustaining porcine kidney xenotransplantation has shown physiological kidney pathway activity in the xenograft setting.
Counter evidence: Compatibility is still a medium-confidence bridge from engineering to human benefit, because rejection, infection, thrombosis, malignancy, surgical complications, and immunosuppression harm can break the chain.; Kidney evidence is ahead of liver and heart evidence in humans; cross-organ generalization is still a hypothesis.
Engineered extracorporeal porcine liver support can bridge acute liver failure
For the liver support program, the causal theory is that a genetically engineered porcine liver connected through an extracorporeal cross-circulation device can temporarily provide liver functions in patients with acute-on-chronic liver failure and hepatic encephalopathy. By supplying detoxification and other liver-support functions outside the body, the intervention is expected to stabilize patients during treatment or bridge them to recovery or transplantation.
Testable predictions include short-term safety of extracorporeal porcine liver perfusion, improved biochemical or neurologic markers of liver failure, successful bridging to transplant or recovery in severe patients, and no detectable porcine retrovirus transmission.
manual entry · Sat Jun 20 2026 03:27:53 GMT+0000 (Coordinated Universal Time)
Popperian evaluation
Premise plausibility7.0
The premise is credible: extracorporeal liver support has already been studied in acute liver failure and acute-on-chronic liver failure, and whole-organ porcine liver perfusion has some historical clinical signal. The biological claim also avoids permanent engraftment, which lowers the burden compared with a full liver xenotransplant. The weak point is functional dose. We do not fully know whether a porcine liver outside the body can provide enough detoxification, synthetic, metabolic, and neurologic stabilization during the treatment window to change outcomes in severe patients.
Supporting evidence: Extracorporeal liver support systems have been studied across nonbiological, biological, and whole-organ perfusion approaches.; Reports of whole-organ extracorporeal liver perfusion found that more than half of severe patients were bridged to transplantation and survived without detectable porcine retrovirus transmission.; Genome engineering can produce pigs modified for xenotransplantation, including edits meant to reduce immune or infectious risk.; Porcine endogenous retroviruses can be inactivated or mitigated with genome-editing strategies.
Counter evidence: Pooled evidence for existing artificial liver support systems has not shown a clear overall mortality benefit.; The core functional assumption remains medium confidence: the device must deliver enough liver function without permanent engraftment.; The claim that extracorporeal use reduces xenotransplantation risk while preserving useful cross-circulation support is still low-confidence.
Gene-edited pig hearts can bridge infants to allotransplantation
For the heart program, the causal theory is that a gene-edited porcine heart can provide temporary but life-sustaining cardiac function in critically ill infants who are poor candidates for mechanical circulatory support. If the xenograft can maintain circulation without causing prohibitive immune sensitization, it could preserve the patient long enough to receive a human allograft.
Testable predictions include multi-month survival after orthotopic cardiac xenotransplantation, stable hemodynamics and echocardiographic function, and little or no xeno- or allo-sensitization that would compromise later human heart transplantation.
publication · Sat Jun 20 2026 03:27:53 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The premise is biologically credible but still preclinical for the target patient group. Gene-edited pig donors have a plausible mechanistic role: reduce immune and infectious barriers enough for a pig heart to function temporarily in a primate recipient. The bridge claim also fits a real clinical gap, because some critically ill infants are poor candidates for mechanical circulatory support. The weak point is translation. A baboon model can show feasibility, but it cannot prove that a human infant will tolerate the surgery, immunosuppression, infection risk, and later human heart transplantation.
Supporting evidence: In the pig-to-baboon pediatric model, 8 of 15 recipients survived more than 1 month, 6 survived more than 3 months, and the longest survivor lived more than 24 months.; Three xenograft-supported baboon recipients were selected for transition to cardiac allotransplantation after more than 4 months of xenograft support.; Genetic engineering of pig donors is supported by work on humanized porcine donors and PERV inactivation.
Counter evidence: The evidence is still animal-model evidence for this exact heart-bridge use case.; Clinical xenotransplantation requires donor screening, pathogen mitigation, recipient monitoring, and infection prevention, which means infectious risk remains a live constraint.
Humanized donor edits reduce immune and hematologic incompatibility
eGenesis' platform implies a causal theory that removing key porcine antigens and adding human proteins can make pig organs less visible or damaging to the human immune and coagulation systems. Triple-knockout pigs expressing multiple human proteins are intended to reduce xenograft rejection, complement injury, inflammation, and thrombotic or hematologic incompatibility that would otherwise prevent durable organ function.
Testable predictions include less antibody-mediated injury, improved graft survival, preserved organ physiology, and reduced markers of complement activation, inflammation, thrombosis, or immune sensitization in primate or human xenotransplant recipients.
publication · Sat Jun 20 2026 03:27:53 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The premise is biologically credible. Pig organs carry carbohydrate antigens and species-specific regulatory signals that can trigger human antibody binding, complement injury, inflammation, rejection, and coagulation dysfunction. Removing major porcine antigens and adding human complement, inflammatory, coagulation, or hematologic regulators is a direct mechanistic answer to those barriers. The weak point is dose and placement: the edit only matters if the human proteins are expressed in the right tissue, at enough level, for long enough.
Supporting evidence: Triple-knockout pigs can remove major porcine carbohydrate antigens implicated in xenograft immune recognition.; Humanized porcine donor designs have been constructed and tested as xenotransplant donors.; The cited 2023 Nature donor-design work and 2021 macaque kidney work directly test edited pig organs carrying multiple human proteins.
Counter evidence: Expression level, tissue distribution, and durability of the added human genes remain material assumptions.; Surgical injury, immunosuppression, infection, preservation damage, and recipient condition can dominate graft outcomes and blur the effect of donor edits.
PERV inactivation lowers infectious risk of xenotransplantation
A specific safety theory is that inactivating porcine endogenous retroviruses in donor pigs reduces the risk that porcine retroviral sequences will infect immunosuppressed human transplant recipients. Because xenotransplantation exposes recipients to living pig tissue under immunosuppression, reducing endogenous retroviral activity is proposed to make porcine organs safer for clinical use.
Testable predictions include absence of PERV transmission in recipients, stable donor genomes with inactive PERV loci, and acceptable infectious-disease surveillance results after transplantation or extracorporeal organ support.
publication · Sat Jun 20 2026 03:27:53 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The premise is credible: PERV sequences are built into pig genomes, xenotransplantation exposes immunosuppressed humans to living pig tissue, and CRISPR work has shown that PERV loci can be inactivated in pig cells and pigs. The weak link is clinical magnitude. The theory assumes that lower PERV activity meaningfully lowers recipient infection risk, but human xenotransplant exposure is still sparse.
Supporting evidence: PERVs are endogenous retroviral sequences in pig genomes with a plausible infectious-risk role in xenotransplantation.; Clinical xenotransplantation uses living pig tissue in immunosuppressed recipients, which creates a real safety concern.; Genome-wide PERV inactivation was reported in 2015, CRISPR-Cas9 PERV inactivation in pigs in 2017, and extensive germline pig genome engineering in 2020.
Counter evidence: The evidence context does not show frequent confirmed PERV infection in human xenotransplant recipients.; Recipient infection risk also depends on donor screening, immunosuppression, surgery, graft injury, and ordinary human pathogens.
Explanatory power5.0
The theory explains why PERV-inactivated donors should look safer on retroviral surveillance, but it does not yet explain much observed clinical variation. Absence of detected PERV transmission after transplant or extracorporeal support fits the theory, but it also fits strict donor screening, short exposure windows, low baseline PERV infectivity, and limited sample size. The hypothesis is biologically neat. The clinical evidence is still thin.
Extracorporeal porcine liver support can bridge acute liver failure
The liver support program's causal theory is that a genetically engineered porcine liver used in extracorporeal cross-circulation can temporarily perform enough liver function to stabilize patients with acute or acute-on-chronic liver failure. This temporary support should reduce near-term mortality or preserve patients long enough for recovery or allotransplantation.
Testable predictions include improved short-term survival, stabilization of hepatic encephalopathy or other liver-failure physiology, successful bridging to transplant, adequate perfusion durability, and absence of porcine retrovirus transmission.
publication · Mon Jun 08 2026 20:28:07 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility7.0
The starting premise is biologically credible: a liver performs detoxification, synthetic, metabolic, and regulatory functions that current artificial support systems only partly mimic, so using a whole porcine liver outside the body is a coherent bridge strategy. The hard part is whether perfusion, coagulation, immune activation, and infection control can hold long enough in very sick ALF or ACLF patients. The premise is plausible, but still rests on a large functional assumption.
Supporting evidence: Whole-organ extracorporeal liver perfusion has been reported in severe ALF or ACLF cases, with some patients bridged to transplantation and survival reported without porcine retrovirus transmission.; Gene-edited pig organs have supported prolonged survival in nonhuman primate and early human xenotransplantation contexts.; Donor pig engineering and PERV inactivation work support the feasibility of reducing immune and infectious barriers.
Counter evidence: Artificial liver support systems have not shown a statistically significant pooled short-term mortality benefit overall.; Evidence from pig kidney and heart xenotransplantation raises plausibility but does not prove that a porcine liver can stabilize human liver-failure physiology.
Engineered kidney xenotransplantation can restore renal function in kidney failure
For EGEN-2784 and the kidney program, the theory is that a genetically engineered porcine kidney can substitute for a failed human kidney closely enough to sustain life and improve health in patients with end-stage kidney disease. By providing a functioning graft when human donor kidneys are unavailable, the intervention should address uremia and the morbidity of chronic kidney failure.
Testable predictions include post-transplant kidney function, reduced dependence on dialysis, manageable rejection and infection risk, and clinical outcomes sufficient to support the Phase 1/2/3 trial enabled by FDA IND clearance.
publication · Mon Jun 08 2026 20:28:07 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The core premise is biologically credible: a kidney is a replacement organ, and the proposed test is whether an engineered pig kidney can perform filtration, fluid and electrolyte control, and related renal functions in a human recipient. The premise is backed by donor genome engineering, nonhuman primate kidney xenotransplant data, and direct human experience. The weak point is duration. The evidence supports short-term and early clinical plausibility better than durable, routine renal replacement.
Supporting evidence: Genome engineering can produce porcine donors with compatibility modifications and reduced porcine endogenous retrovirus risk.; Nonhuman primate studies report renal support from genetically modified pig kidneys under immunosuppression.; Human porcine kidney xenotransplantation reports provide direct clinical evidence in end-stage kidney disease.
Counter evidence: The evidence base is still early, with limited living human recipient data.; The theory depends on avoiding immunologic, hematologic, infectious, and malignant complications under heavy monitoring.
Explanatory power7.0
The theory explains the observed kidney-function signals directly: if the xenograft filters and regulates fluid chemistry, renal markers should improve and dialysis need should fall. That is a clean causal chain. Still, early clinical success could reflect intensive perioperative care, immunosuppression, and patient selection as much as the graft design itself. The theory explains the main observations, but it has not yet beaten those alternatives across enough patients or time.
PERV inactivation improves xenotransplant infectious safety
eGenesis' platform includes inactivation of porcine endogenous retroviruses. The causal theory is that eliminating or suppressing infectious retroviral risk from porcine donors should make xenotransplantation safer for immunosuppressed human recipients, reducing a major barrier to durable organ replacement.
Testable predictions include absence of porcine retrovirus transmission after transplant or extracorporeal support, acceptable infectious complication rates, and successful donor screening and recipient monitoring protocols in clinical xenotransplantation.
publication · Mon Jun 08 2026 20:28:07 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The starting premise is credible: eGenesis edits donor pigs to inactivate porcine endogenous retroviruses, and PERVs are a real theoretical infectious risk when pig tissue enters an immunosuppressed human recipient. The weak point is magnitude. The theory assumes that PERV inactivation meaningfully lowers clinical infection risk, but current human evidence is still too small to estimate how much risk was removed.
Supporting evidence: eGenesis' donor platform includes PERV inactivation in genetically engineered pigs.; PERVs are identified as a potential pig-to-human infectious risk in xenotransplantation, especially under immunosuppression.; CRISPR work in 2015 and 2017 supports the technical premise that PERV sequences can be inactivated genome-wide.
Counter evidence: PERV inactivation alone does not make xenotransplantation infectious-safe; donor screening, pathogen mitigation, infection prevention, and post-transplant monitoring remain required.; The evidence context does not provide a large clinical comparison of PERV-inactivated donors versus PERV-competent donors.
Explanatory power6.0
The theory explains one narrow part of the observed safety signal: no detected porcine retrovirus transmission after exposure to gene-edited pig tissue fits the PERV-risk model. It does not explain the broader infectious safety profile by itself. Screening, monitoring, immunosuppression management, recipient history, and other pathogen controls are all live alternative explanations. PERV inactivation is a plausible contributor, not the whole infectious disease story.
Multiplex edits reduce xenograft immune incompatibility
The company's platform uses multiplex genome engineering, including triple gene knockout and human transgene insertion, to make porcine organs more human-compatible. The implied mechanism is that removing problematic pig genetic features while adding human proteins should reduce immunologic and physiologic incompatibility between the graft and recipient, allowing the transplanted organ to survive and function longer.
Testable predictions include lower acute rejection or xenograft injury, longer graft survival in nonhuman primates or humans, preserved kidney or heart function, and reduced xeno- or allo-sensitization during xenograft support.
publication · Mon Jun 08 2026 20:28:07 GMT+0000 (Coordinated Universal Time) ·
SourcePopperian evaluation
Premise plausibility8.0
The premise is biologically credible. Pig antigens, complement activity, coagulation mismatch, inflammation, and viral safety risks are real barriers in xenotransplantation, and the platform targets several of them with gene knockouts plus human transgenes. The weak point is sufficiency: the evidence itself says edits alone do not carry the graft. Immunosuppression, surgery, donor screening, monitoring, and infection control still matter.
Supporting evidence: Multiplex genome engineering can create porcine donor organs with pig gene knockouts and human transgene insertions.; Triple-knockout pigs expressing multiple human proteins have been used as kidney xenograft donors in nonhuman primates.; Humanized porcine donors can be designed and tested using extensive genome editing.
Counter evidence: The causal role of each edited gene is treated as a medium-confidence assumption rather than a fully proven chain.; Genetic compatibility edits are not sufficient on their own; graft success also requires immunosuppression, surgical execution, donor screening, monitoring, and infection prevention.
